Hauptseite > Publikationsdatenbank > Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients > print

001     154144
005     20210129213837.0
024 7 _ |a 10.1038/mp.2014.56
|2 doi
024 7 _ |a 1476-5578
|2 ISSN
024 7 _ |a 1359-4184
|2 ISSN
024 7 _ |a 2128/8462
|2 Handle
024 7 _ |a WOS:000349986700001
|2 WOS
024 7 _ |a altmetric:2404228
|2 altmetric
024 7 _ |a pmid:24888364
|2 pmid
037 _ _ |a FZJ-2014-03537
082 _ _ |a 610
100 1 _ |0 P:(DE-HGF)0
|a Frank, J.
|b 0
|e Corresponding Author
245 _ _ |a Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients
260 _ _ |a London
|b Macmillan
|c 2015
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1427449481_8870
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 0
|2 EndNote
|a Journal Article
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |2 DRIVER
|a article
520 _ _ |a Schizophrenia is a severe neuropsychiatric disorder that affects around 0.5–1% of the population. Research has shown that early intervention increases the likelihood of remission and reduces the severity of symptoms, as well as attenuates the decline in social and overall functioning.1Around 30% of patients fail to respond adequately to the usual antipsychotic medications, and are classified as being treatment resistant. These patients can be treated with the atypical antipsychotic clozapine, the only evidence-based pharmacotherapy for treatment-resistant schizophrenia. However, clozapine is associated with severe adverse events and is thus only prescribed in patients who have failed to respond to trials of two other antipsychotics. This process may take many years. Since an extended duration of untreated psychosis and lack of efficacy for the initial treatment are however associated with a poorer prognosis,6 identification of patients who will eventually require clozapine is an important goal for improving clinical outcome. Research to identify clinical predictors of response prior to treatment initiation has shown that premorbid social functioning (PSF) is among the most reliable measures (for a review see Schennach et al.6). Furthermore, reports of an association between a family history of psychosis and an unfavourable treatment response7 suggest the influence of genetic factors. However, few candidate gene studies have been conducted and their results are inconsistent.
536 _ _ |0 G:(DE-HGF)POF3-571
|a 571 - Connectivity and Activity (POF3-571)
|c POF3-571
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, juser.fz-juelich.de
700 1 _ |0 P:(DE-HGF)0
|a Lang, M.
|b 1
700 1 _ |0 P:(DE-HGF)0
|a Witt, S. H.
|b 2
700 1 _ |0 P:(DE-HGF)0
|a Strohmaier, J.
|b 3
700 1 _ |0 P:(DE-HGF)0
|a Rujescu, D.
|b 4
700 1 _ |0 P:(DE-Juel1)140234
|a Cichon, S.
|b 5
700 1 _ |0 P:(DE-HGF)0
|a Degenhardt, F.
|b 6
700 1 _ |0 P:(DE-HGF)0
|a Nöthen, M. M.
|b 7
700 1 _ |0 P:(DE-HGF)0
|a Collier, D. A.
|b 8
700 1 _ |0 P:(DE-HGF)0
|a Ripke, S.
|b 9
700 1 _ |0 P:(DE-HGF)0
|a Naber, D.
|b 10
700 1 _ |0 P:(DE-HGF)0
|a Rietschel, M.
|b 11
|e Corresponding Author
773 _ _ |0 PERI:(DE-600)1502531-7
|a 10.1038/mp.2014.56
|p 150-151
|t Molecular psychiatry
|v 20
|x 1476-5578
|y 2015
856 4 _ |u https://juser.fz-juelich.de/record/154144/files/FZJ-2014-03537.pdf
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/154144/files/FZJ-2014-03537.jpg?subformat=icon-144
|x icon-144
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/154144/files/FZJ-2014-03537.jpg?subformat=icon-180
|x icon-180
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/154144/files/FZJ-2014-03537.jpg?subformat=icon-640
|x icon-640
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:154144
|p openaire
|p open_access
|p driver
|p VDB
|p dnbdelivery
910 1 _ |0 I:(DE-588b)5008462-8
|6 P:(DE-Juel1)140234
|a Forschungszentrum Jülich GmbH
|b 5
|k FZJ
913 0 _ |0 G:(DE-HGF)POF2-333
|1 G:(DE-HGF)POF2-330
|2 G:(DE-HGF)POF2-300
|a DE-HGF
|b Gesundheit
|l Funktion und Dysfunktion des Nervensystems
|v Pathophysiological Mechanisms of Neurological and Psychiatric Diseases
|x 0
913 1 _ |0 G:(DE-HGF)POF3-571
|1 G:(DE-HGF)POF3-570
|2 G:(DE-HGF)POF3-500
|a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|v Connectivity and Activity
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2015
915 _ _ |0 LIC:(DE-HGF)CCBYNCSA3
|2 HGFVOC
|a Creative Commons Attribution-NonCommercial-ShareAlike CC BY-NC-SA 3.0
915 _ _ |0 StatID:(DE-HGF)0010
|2 StatID
|a JCR/ISI refereed
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
915 _ _ |0 StatID:(DE-HGF)0110
|2 StatID
|a WoS
|b Science Citation Index
915 _ _ |0 StatID:(DE-HGF)0111
|2 StatID
|a WoS
|b Science Citation Index Expanded
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Thomson Reuters Master Journal List
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
915 _ _ |0 StatID:(DE-HGF)0310
|2 StatID
|a DBCoverage
|b NCBI Molecular Biology Database
915 _ _ |0 StatID:(DE-HGF)0510
|2 StatID
|a OpenAccess
915 _ _ |0 StatID:(DE-HGF)1030
|2 StatID
|a DBCoverage
|b Current Contents - Life Sciences
915 _ _ |0 StatID:(DE-HGF)1050
|2 StatID
|a DBCoverage
|b BIOSIS Previews
920 1 _ |0 I:(DE-Juel1)INM-1-20090406
|k INM-1
|l Strukturelle und funktionelle Organisation des Gehirns
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a FullTexts
980 _ _ |a I:(DE-Juel1)INM-1-20090406
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21